Stockreport

Rhythm Pharmaceuticals Completes Enrollment of Pivotal Cohort in Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström Syndromes

Rhythm Pharmaceuticals, Inc.  (RYTM) 
Last rhythm pharmaceuticals, inc. earnings: 3/8 08:12 am Check Earnings Report
US:NASDAQ Investor Relations: ir.rhythmtx.com
PDF -- Topline data expected in the fourth quarter of 2020 or early in the first quarter of 2021 -- -- Supplemental cohort continues enrollment to meet patient demand -- [Read more]